Group One Trading’s Arbutus Biopharma ABUS Stock Holding History

Group One Trading’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$292K	Buy	64,800 +18,200	+39%	+$79.6K	﹤0.01%	3817
2025 Q4	$224K	Sell	46,600 -15,100	-24%	-$67.9K	﹤0.01%	4278
2025 Q3	$280K	Buy	61,700 +15,100	+32%	+$55.5K	﹤0.01%	4297
2025 Q2	$144K	Buy	46,600 +34,100	+273%	+$113K	﹤0.01%	4655
2025 Q1	$43.6K	Sell	12,500 -26,500	-68%	-$88.4K	﹤0.01%	5267
2024 Q4	$128K	Sell	39,000 -40,400	-51%	-$149K	﹤0.01%	4314
2024 Q3	$306K	Sell	79,400 -39,200	-33%	-$150K	﹤0.01%	3252
2024 Q2	$366K	Buy	118,600 +2,000	+2%	+$6K	﹤0.01%	2853
2024 Q1	$301K	Sell	116,600 -235,500	-67%	-$610K	﹤0.01%	3212
2023 Q4	$880K	Buy	352,100 +152,300	+76%	+$298K	﹤0.01%	2567
2023 Q3	$406K	Sell	199,800 -51,300	-20%	-$108K	﹤0.01%	3113
2023 Q2	$578K	Sell	251,100 -8,600	-3%	-$22.4K	﹤0.01%	2872
2023 Q1	$787K	Sell	259,700 -16,900	-6%	-$47.7K	﹤0.01%	2344
2022 Q4	$644K	Sell	276,600 -32,700	-11%	-$78.2K	﹤0.01%	2805
2022 Q3	$591K	Sell	309,300 -303,000	-49%	-$713K	﹤0.01%	3073
2022 Q2	$1.66M	Buy	612,300 +224,200	+58%	+$574K	﹤0.01%	2221
2022 Q1	$1.16M	Sell	388,100 -623,500	-62%	-$1.91M	﹤0.01%	2948
2021 Q4	$3.94M	Buy	1,011,600 +763,900	+308%	+$2.97M	﹤0.01%	1920
2021 Q3	$1.06M	Buy	247,700 +90,500	+58%	+$302K	﹤0.01%	3347
2021 Q2	$476K	Buy	157,200 +9,300	+6%	+$28.8K	﹤0.01%	4268
2021 Q1	$493K	Buy	147,900 +500	+0.3%	+$1.93K	﹤0.01%	4051
2020 Q4	$523K	Buy	147,400 +75,800	+106%	+$265K	﹤0.01%	3221
2020 Q3	$224K	Sell	71,600 -307,300	-81%	-$935K	﹤0.01%	3561
2020 Q2	$690K	Sell	378,900 -44,300	-10%	-$72.5K	﹤0.01%	2357
2020 Q1	$427K	Buy	423,200 +330,600	+357%	+$894K	﹤0.01%	2162
2019 Q4	$257K	Buy	+92,600	New	+$150K	﹤0.01%	2979
2019 Q3	–	Sell	-1,100	Closed	-$2K	–	5072
2019 Q2	$2K	Sell	1,100 -2,300	-68%	-$5.88K	﹤0.01%	4740
2019 Q1	$12K	Sell	3,400 -19,500	-85%	-$74.9K	﹤0.01%	4201
2018 Q4	$88K	Sell	22,900 -700	-3%	-$3.45K	﹤0.01%	3245
2018 Q3	$223K	Buy	23,600 +4,400	+23%	+$43.7K	﹤0.01%	2938
2018 Q2	$140K	Sell	19,200 -7,000	-27%	-$41.7K	﹤0.01%	3334
2018 Q1	$131K	Buy	26,200 +12,800	+96%	+$67.8K	﹤0.01%	3082
2017 Q4	$68K	Buy	13,400 +10,400	+347%	+$61K	﹤0.01%	3565
2017 Q3	$19K	Hold	3,000	–	–	﹤0.01%	4080
2017 Q2	$11K	Buy	+3,000	New	+$10.3K	﹤0.01%	4170
2017 Q1	–	Sell	-10,300	Closed	-$25K	–	4567
2016 Q4	$25K	Hold	10,300	–	–	﹤0.01%	3602
2016 Q3	$35K	Sell	10,300 -3,500	-25%	-$13.7K	﹤0.01%	3535
2016 Q2	$48K	Buy	13,800 +1,000	+8%	+$4.23K	﹤0.01%	3322
2016 Q1	$53K	Buy	12,800 +5,400	+73%	+$19.3K	﹤0.01%	3224
2015 Q4	$33K	Sell	7,400 -62,100	-89%	-$340K	﹤0.01%	3646
2015 Q3	$423K	Sell	69,500 -14,000	-17%	-$124K	0.01%	1908
2015 Q2	$990K	Sell	83,500 -383,100	-82%	-$5.83M	0.01%	1216
2015 Q1	$8.15M	Buy	466,600 +163,500	+54%	+$3.35M	0.13%	137
2014 Q4	$4.59M	Buy	303,100 +59,900	+25%	+$1.03M	0.07%	320
2014 Q3	$5.14M	Buy	243,200 +229,800	+1,715%	+$3.75M	0.08%	285
2014 Q2	$175K	Sell	13,400 -36,200	-73%	-$513K	﹤0.01%	2543
2014 Q1	$1.07M	Buy	+49,600	New	+$891K	0.02%	1038

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Group One Trading's ABUS Position: Q1 2026 in Review

Group One Trading reduced its Arbutus Biopharma (ABUS) stake by 13% in Q1 2026, selling an estimated $33.1K and leaving 50,843 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #4003.

Group One Trading first reported a position in ABUS in Q1 2014 and has held it in 36 quarters since. The position peaked at $1.4M in Q4 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Group One Trading held 50,843 shares of Arbutus Biopharma worth $229K as of Q1 2026.
Group One Trading sold 7,573 Arbutus Biopharma shares in Q1 2026, an estimated $33.1K.
Arbutus Biopharma made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4003 holding.
Group One Trading first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 36 quarters since.
Group One Trading's Arbutus Biopharma position peaked at $1.4M in Q4 2021.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.